Cargando…

Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer

We report the case of a 64-year-old man with advanced small-cell lung cancer who developed fulminant amoebic colitis during cytotoxic chemotherapy. During the first cycle of carboplatin/etoposide treatment, febrile neutropenia and grade 4 neutropenia developed. Because diarrhea, abdominal pain, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitaoka, Aya, Tanimura, Kazuya, Yasuda, Yuto, Nishioka, Kensuke, Hirayama, Yutaka, Uemasu, Kiyoshi, Iwashima, Daisuke, Arita, Sou, Kitai, Toshiyuki, Hoshi, Susumu, Date, Emi, Iizuka, Norishige, Takahashi, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605421/
https://www.ncbi.nlm.nih.gov/pubmed/34840954
http://dx.doi.org/10.1016/j.idcr.2021.e01337
_version_ 1784602174342299648
author Kitaoka, Aya
Tanimura, Kazuya
Yasuda, Yuto
Nishioka, Kensuke
Hirayama, Yutaka
Uemasu, Kiyoshi
Iwashima, Daisuke
Arita, Sou
Kitai, Toshiyuki
Hoshi, Susumu
Date, Emi
Iizuka, Norishige
Takahashi, Ken-ichi
author_facet Kitaoka, Aya
Tanimura, Kazuya
Yasuda, Yuto
Nishioka, Kensuke
Hirayama, Yutaka
Uemasu, Kiyoshi
Iwashima, Daisuke
Arita, Sou
Kitai, Toshiyuki
Hoshi, Susumu
Date, Emi
Iizuka, Norishige
Takahashi, Ken-ichi
author_sort Kitaoka, Aya
collection PubMed
description We report the case of a 64-year-old man with advanced small-cell lung cancer who developed fulminant amoebic colitis during cytotoxic chemotherapy. During the first cycle of carboplatin/etoposide treatment, febrile neutropenia and grade 4 neutropenia developed. Because diarrhea, abdominal pain, and bloody stool were observed, abdominal computed tomography was performed, showing intussusception, and extensive colectomy and colostomy were performed. Histopathology of the colon revealed gastrointestinal necrosis and perforation due to Entamoeba histolytica infection. Amoebiasis improved after treatment with metronidazole and paromomycin. The second cycle of carboplatin/etoposide with dose reduction was completed, resulting in a partial response to small-cell lung cancer. The results of this case suggest that paromomycin is an additional option for amoebiasis during cytotoxic chemotherapy, and persistent diarrhea during cytotoxic chemotherapy should alert clinicians to consider the development of amoebiasis.
format Online
Article
Text
id pubmed-8605421
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86054212021-11-26 Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer Kitaoka, Aya Tanimura, Kazuya Yasuda, Yuto Nishioka, Kensuke Hirayama, Yutaka Uemasu, Kiyoshi Iwashima, Daisuke Arita, Sou Kitai, Toshiyuki Hoshi, Susumu Date, Emi Iizuka, Norishige Takahashi, Ken-ichi IDCases Article We report the case of a 64-year-old man with advanced small-cell lung cancer who developed fulminant amoebic colitis during cytotoxic chemotherapy. During the first cycle of carboplatin/etoposide treatment, febrile neutropenia and grade 4 neutropenia developed. Because diarrhea, abdominal pain, and bloody stool were observed, abdominal computed tomography was performed, showing intussusception, and extensive colectomy and colostomy were performed. Histopathology of the colon revealed gastrointestinal necrosis and perforation due to Entamoeba histolytica infection. Amoebiasis improved after treatment with metronidazole and paromomycin. The second cycle of carboplatin/etoposide with dose reduction was completed, resulting in a partial response to small-cell lung cancer. The results of this case suggest that paromomycin is an additional option for amoebiasis during cytotoxic chemotherapy, and persistent diarrhea during cytotoxic chemotherapy should alert clinicians to consider the development of amoebiasis. Elsevier 2021-11-16 /pmc/articles/PMC8605421/ /pubmed/34840954 http://dx.doi.org/10.1016/j.idcr.2021.e01337 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Kitaoka, Aya
Tanimura, Kazuya
Yasuda, Yuto
Nishioka, Kensuke
Hirayama, Yutaka
Uemasu, Kiyoshi
Iwashima, Daisuke
Arita, Sou
Kitai, Toshiyuki
Hoshi, Susumu
Date, Emi
Iizuka, Norishige
Takahashi, Ken-ichi
Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer
title Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer
title_full Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer
title_fullStr Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer
title_full_unstemmed Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer
title_short Successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer
title_sort successful treatment with metronidazole and paromomycin for fulminant amoebic colitis during cytotoxic chemotherapy in a patient with small-cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605421/
https://www.ncbi.nlm.nih.gov/pubmed/34840954
http://dx.doi.org/10.1016/j.idcr.2021.e01337
work_keys_str_mv AT kitaokaaya successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT tanimurakazuya successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT yasudayuto successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT nishiokakensuke successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT hirayamayutaka successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT uemasukiyoshi successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT iwashimadaisuke successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT aritasou successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT kitaitoshiyuki successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT hoshisusumu successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT dateemi successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT iizukanorishige successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer
AT takahashikenichi successfultreatmentwithmetronidazoleandparomomycinforfulminantamoebiccolitisduringcytotoxicchemotherapyinapatientwithsmallcelllungcancer